{
    "htn": {
        "prefix": "htnn",
        "body": [
            "hypertension"
        ],
        "description": "\u4e16\u4e0a\u7684"
    },
    "prechemo_breast": {
        "prefix": "prechemo_breast",
        "body": [
            "#### Education",
            "",
            "- arranged Por-A implentation",
            "- explained reason of adjuvant chemotherapy: cure and lower the risk of recurrence/metastasis.",
            "  - most likely metastasis sites: liver, brain, lung, bone.",
            "  - if metastasis, the 5-year survival rate is 26%",
            "- explained chemotherapy schedule: `___` CAF or AC followed by T",
            "  - OPD setting, no need for hospitalization",
            "- explained potential chemotherapy toxicities:",
            "  - common: fatigue, alopecia(reversible), nause/vomting, febrile neutropenia, opportunistic infection, infusion reaction (21% to 40% )",
            "  - cyclophosphamide: bone marrow function compromised, hemorrhagic cystitis, secondary leukemia ( 0.5% \u5343\u5206\u4e4b\u4e00)",
            "  - `___` doxorubicin: cardiotoxicity, life-time culmucation 450-500 mg/BSA ( `___` 240 `___` 300mg/BSA throught this course)",
            "  - `___` fluorouracil: stomatitis or esophagopharyngitis, leukopenia, vomiting, diarrhea, frequent bowel movements, watery stools, gastrointestinal ulcer or bleeding, hand-foot syndrome",
            "  - `___` docetaxel: stomatitis, persistent febrile neutropenia, cutaneous reactions, moderate neurosensory effects, secondary leukemia ( 0.5% )",
            "- explained potential endorcine therapy toxicities:",
            "  - AI: hot flashes, arthralgia, flushing, asthenia, edema, headache, osteoporosis and fractures, hypercholesterolemia, hepatic impairment",
            "- explained potential ICI toxicities:",
            "  - pembrolizumab: skin rash pneumonitis, colitis, hepatitis, hypophysitis, thyroid dysfunction, diabetes mellitus",
            "- suggested high protein diet, not suggested additional supplement because it may confound the lab, which may lead to postponed the chemotherapy schedule.",
            "- informed patient to avoid raw food, include fish, meat, vegetable"
        ],
        "description": "\u75c5\u4eba\u9996\u6b21\u270c\ufe0f \u63a5\u53d7\u4e73\u764c\u5316\u7642\u7684 \u2192 \u5fc5\u505a\u6e05\u55ae"
    },
    "temp_BCA": {
        "prefix": "breast_opd",
        "body": [
            "<>-year-old woman, presented for <> due to"
        ],
        "description": "temp_BCA"
    },
    "PMH": {
        "prefix": "PMH",
        "body": [
            "## MEDICAL HISTORY AND RISK FACTORS",
            "",
            "- denied HTN, DM, viral hepatitis",
            "- Obstetric/Gynecologic:",
            "  - G<>P<>AA<>SA",
            "  - Age at first pregnancy:",
            "  - Age at first menarche: < 14 >",
            "  - LMP: < YYYY-MM-DD >",
            "  - <> days per cycle, <> days with < moderate > amount",
            "  - \\*or postmeopause at age <>",
            "  - HRT: < for contraception, for postmeopausal symtpom >",
            "  - breast feeding: < one month >",
            "- Past surgical history:",
            "  - NIL",
            "  - < disease > - < operation > - in < hosptial > - in age <>",
            "- Allergy: NKDA < >",
            "- Concurrent medication/supplement/herb:",
            "  - NIL",
            "  - <>",
            "- Personal/Social history:",
            "  - Smoking history: < denied > < pack per year >, < from age **to** >",
            "  - Alcohol consumption: < calculate: Beer, 5%(250ml)/1unit >",
            "  - Betel nuts: denied",
            "  - Recreational drug: < cannabis, amphetamine, etc. >",
            "  - Occupation: <>",
            "  - Residence: Taipei City <>",
            "  - Education Level: college <>",
            "- Family history:",
            "  - Siblings [1] <> [2] <> [3] <>",
            "  - lives with husband (age <>) and < sons, mother in law, boyfriend, roomate...>",
            "  - mother of [1] < son/daugher > ( < age > ) [2]",
            "  - Family cancer history:",
            "    - < breast cancer > - maternal <>, diagnosed at age <>",
            "    - < prostate cancer > - paternal <>, diagnosed at age <>",
            "  - Other family medical history:",
            "    - < e.g. HTN > - < mother >",
            "    - < DM > - < paternal > < grandmother >"
        ],
        "description": "\u904e\u53bb\u75c5\u53f2\uff0c\u7531\u5176\u5c0d\u65bc\u4e73\u764c\u75c5\u4eba\u8d85\u7d1a\u91cd\u8981\uff0c\u9700\u8981\u586b\u4e00\u5927\u5806\u91cd\u8981\u7684 \u2192 \u8868\u683c\uff01\uff01\uff01"
    },
    "breast cancer assessment": {
        "prefix": "breast.ass",
        "body": [
            "- Rt/Lt<> breast cancer (<>'/<>cm), histology: <>",
            "- <>T<>N<>(<>/<>)M<>, Stage <>",
            "- NG2, ER/PR/HER2: <>/<>/<>, Ki-67=<>%"
        ],
        "description": "breast cancer assessment"
    },
    "Trastuzumab": {
        "prefix": "herceptin",
        "body": [
            "- Mechanism: Binds to HER2",
            "- Dosing: Loading dose 4-8 mg/kg IV, followed by 2-6 mg/kg maintenance dose IV weekly or every 21 d",
            "- PK/PD: T1/2 \u223c6-16 d",
            "- AEs: CMP (DLT), GI upset, rash, fever, pain",
            "- DDI: Anthracyclines (potential \u2191 in cardiac tox)",
            "-",
            "",
            "[[protocol-of-Trastuzumab]]",
            "",
            "- [[Polymorphisms]]"
        ],
        "description": "Trastuzumab"
    },
    "cyclophosphamide": {
        "prefix": "cyc",
        "body": [
            "\u9810\u9632\u7528\u85e5\uff1a",
            "",
            "[[Mesna]] UROMITEXAN 400MG",
            "",
            "- SLE",
            "",
            "  - for Severe organ-threatening nephritis or CNS disease (induction, minimize exposure)",
            "",
            "- S/E",
            "  - Cytopenias,",
            "  - infertility/teratogen,",
            "  - myeloprolif. dis.,",
            "  - hemorrhagic cystitis,",
            "  - bladder cancer"
        ],
        "description": "cyclophosphamide"
    },
    "endoxan": {
        "prefix": "endoxan",
        "body": [
            ""
        ],
        "description": "endoxan"
    },
    "5FU": {
        "prefix": "5FU",
        "body": [
            "- Dosing: Dose, schedule, & administration (IVB vs. IV continuous infusion) are based on malignancy. Common ranges, IVB: 400-600 mg/m2/dose; IV continuous infusion 200-1,500 mg/m2/d. No renal or hepatic dose adjustments recommended; use w/ caution",
            "- PK/PD: Extensive tissue distribution; saturable catabolism; excretion via metabolism, lung, & urine; T1/2 8-20 min after IVB",
            "- AEs: Dependent on dose & administration (IV bolus vs. IV continuous infusion), diarrhea (DLT), mucositis (DLT), N/V (low emetogenic potential), myelosuppression (bolus > continuous infusion), neurotoxicity, coronary artery vasospasm, conjunctivitis, hand-foot syndrome (continuous infusion > bolus), alopecia, nail changes",
            "- DDI: CYP2C9 substrates (\u2193 substrate levels), cimetidine (\u2193 clearance of 5-FU), oral anticoagulants (\u2191 levels of anticoagulants), leucovorin (\u2191 tox of 5-FU)",
            "- Clinical pearls: AEs w/ DPD deficiency (prolonged clearance, \u2191 tox), radiosensitizer; leucovorin is given w/ bolus administration to \u2191 intracellular half-life of 5-FU (\u2191 cytotoxicity). Uridine triacetate used as antidote in cases of overdose or DPD deficiency"
        ],
        "description": "5FU"
    },
    "breast-exam-findings": {
        "prefix": "breastpe",
        "body": [
            "Physical breast examination: <> Inflammatory <> Peau d\u2019orange <> Palpable lymph nodes <> Nipple secretion"
        ],
        "description": "breast-exam-findings"
    },
    "template": {
        "prefix": "slide_open_and_end",
        "body": [
            "<!-- _paginate: false -->",
            "<!-- _header: '' -->",
            "",
            "#### KFSYSCC",
            "",
            "# TITLE",
            "",
            "<img src=\"https://img.shields.io/badge/and-is_result-6c9a77\"/>",
            "",
            "## \u6797\u5354\u9706\uff0cFellow 1",
            "",
            "press <kbd>Ctrl</kbd> and <kbd>t</kbd>then",
            "",
            "---",
            "",
            "${1:content here}",
            "",
            "---",
            "",
            "# Thank you for your time and attention",
            "",
            "# _Have a nice day_",
            "",
            "![emojik RLQ height:300px](https://emojik.vercel.app/s/\u2600\ufe0f_\ud83d\ude0e?size=256)"
        ],
        "description": "template"
    },
    "chemo_temp_CAF": {
        "prefix": "CAF",
        "body": [
            "(Cycled every 21 days for 6 cycles)",
            "",
            "- Cyclophosphamide 500 mg/m2 IV",
            "- Doxorubicin 50 mg/m2 IV",
            "- Fluorouracil 500 mg/m2 IV"
        ],
        "description": "chemo_temp_CAF"
    },
    "MINIPE": {
        "prefix": "minipe",
        "body": [
            "## PHYSICAL EXAM",
            "",
            "alert<> and oriented<>, appeared in no distress<>",
            "No<Anemia> conjunctival pallor,<> no<> scleral icterus",
            "HEENT: no<> oral thrush,<> no neck LAP",
            "Chest: bilateral<> clear<> breath sounds",
            "[Optional] Breast:<>no inflammatory,<>no Peau d'orange,<>no Palpable LN,<>no Nipple secretion",
            "Heart: regular rhythm,<> normal rate,<>no murmur",
            "Abd: non<>distended, normo<>active BoS, nontender",
            "Ext: warm, <bilateral 2+>no<> pitting edema"
        ],
        "description": "MINIPE"
    },
    "Procedure_Note_CVC": {
        "prefix": "CVC",
        "body": [
            "- indication: hemodynamic monitoring`___`intravenous access `___`stem cell harvest`___`hemodialysis `___`",
            "- ultrasound-guided: yes",
            "- position: right internal jugular vein. `___` right femoral vein `___`",
            "- catheter: Non-tunneled central venous catheter `___`, large `___` small `___` bore",
            "- estimated blood loss: 3ml",
            "- CXR: catheter tip at cavo-atrial junction (2.5cm below carina)"
        ],
        "description": "Procedure_Note_CVC"
    },
    "Smart Brevity": {
        "prefix": "Smart",
        "body": [
            "## \u6a19\u984c: ${1:\u7528 6-10 \u500b\u5b57}",
            "",
            "TLDR: \u958b\u5834(\u4e00\u53e5\u77ed\u8a9e): ${2:\u8b80\u8005\u77e5\u9053\u3001\u60f3\u77e5\u9053\u3001\u61c9\u8a72\u77e5\u9053}",
            "",
            "## \ud83c\udf1f\u8981\u9ede",
            "",
            "${3:\u89e3\u91cb\u70ba\u4ec0\u9ebc\u9019\u4ef6\u4e8b\u60c5\u5f88\u91cd\u8981}",
            "",
            "## \ud83d\udcda\u8a73\u7d30\u5167\u5bb9",
            "",
            "${4:\u8b80\u8005\u53ef\u9078\u64c7\u662f\u5426\u8981\u7e7c\u7e8c\u5f80\u4e0b\u8b80\u66f4\u591a\u5167\u5bb9}"
        ],
        "description": "Smart Brevity"
    },
    "Regional Lymph Nodes-of-Staging of breast cancer": {
        "prefix": "breast_LN",
        "body": [
            "- N1 (1-3 axillary nodes)",
            "- N2 (4-9 axillary nodes)",
            "- N3 (\u226510 axillary nodes or any infraclavicular or ipsilateral supraclavicular nodes);",
            "",
            "## The regional lymph nodes are",
            "",
            "> \u56db\u5927\u5340\u57df\u6c7a\u5b9a\u671f\u5225\uff0c\u5176\u4e2d\u814b\u4e0b\u9084\u53ef\u4ee5 \u2714 \u5206\u4f4e\u4e2d\u9ad8\uff0c\u5176\u4e2dinfraclavicular & III \u7b97\u4e00\u6a23",
            "",
            "1. Axillary (ipsilateral): interpectoral (Rotter) nodes and lymph nodes along the axillary",
            "vein and its tributaries, which may be divided into the following levels:",
            "    - (i) Level I (low-axilla): lymph nodes lateral to the lateral border of pectoralis minor muscle.",
            "    - (ii) Level II (mid-axilla): lymph nodes between the medial and lateral borders of the pectoralis minor muscle and the interpectoral (Rotter) lymph nodes.",
            "    - (iii) Level III (apical axilla): apical lymph nodes and those medial to the medial margin of the pectoralis minor muscle, excluding those designated as subclavicular or infraclavicular.",
            "2. Infraclavicular (subclavicular) (ipsilateral).",
            "3. Internal mammary (ipsilateral): lymph nodes in the intercostal spaces along the edge",
            "of the sternum in the endothoracic fascia.",
            "4. Supraclavicular (ipsilateral).",
            "",
            "[[figure-of-Regional Lymph Nodes-of-Staging of breast cancer]]",
            "",
            "> \u53ef\u4ee5 \u2716 \u4e0d\u53ef\u4ee5 \u2714 \u52d5\u5f88\u91cd\u8981\uff0c\u9ecf\u4f4f\u7b97N2",
            "",
            "- NX Regional lymph nodes cannot be assessed (e.g., previously removed)",
            "- N0 No regional lymph node metastasis",
            "  - N(i): micrometastasis 0.2mm, less than 200cell/hpf",
            "- N1 : movable ipsilateral level I, II axillary lymph node(s) (Fig. 327)",
            "- N2 : ipsilateral level I, II axillary lymph node(s) that are clinically fixed or matted; or in clinically detected* ipsilateral internal mammary lymph node(s) in",
            "- the absence of clinically evident axillary lymph node metastasis",
            "  - N2a : axillary lymph node(s) fixed to one another (matted) or to other structures (Fig. 328)",
            "  - N2b : only in clinically detected* internal mammary lymph node(s) and in the absence of clinically evident axillary lymph node metastasis (Fig. 329)",
            "- N3 : ipsilateral infraclavicular (level III axillary) lymph node(s) with or without level I, II axillary lymph node involvement; or in clinically detected* ipsilateral internal mammary lymph node(s) with clinically evident level I, II axillary lymph node metastasis; or : ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement",
            "  - N3a : infraclavicular lymph node(s) (Fig. 330)",
            "  - N3b : internal mammary and axillary lymph nodes (Fig. 331)",
            "  - N3c : supraclavicular lymph node(s) (Fig. 332)"
        ],
        "description": "Regional Lymph Nodes-of-Staging of breast cancer"
    },
    "ACbyT": {
        "prefix": "ACbyT",
        "body": [
            "- Cyle 1-4 (Cycled every 3 weeks)",
            "  - Doxorubicin 60 mg/m2, Cyclophosphamide 600 mg/m2",
            "- Cycle 5-8 (Cycled every 3 weeks)",
            "  - Docetaxel* 60 mg/m2"
        ],
        "description": "ACbyT"
    },
    "peau d orange": {
        "prefix": "orange-peel",
        "body": [
            "- Erythematous, warm, and edematous skin plaques with prominent hair follicles that resemble orange peel",
            "- Caused by obstruction of the lymphatic channels due to tumor growth"
        ],
        "description": "peau d orange"
    },
    "protocol-of-Trastuzumab": {
        "prefix": "h",
        "body": [
            "(Cycled every 3 weeks for 17cycles)",
            "",
            "- Loading(week 1) 8 mg/kg IVF over 90 mins",
            "- Maintenance(week 2 to 17): 6 mg/kg IVF over 90 mins",
            "- AEs: severe CHF (congestive heart failure, 0.54%), symptomatic CHF(1.73%), decrease in LVEF (7.08%), febrile neutropenia (breast cancer, 23%; gastric cancer, 5% ), neutropenia, grade 3 and 4 (32% to 34%), thrombocytopenia, grade 3 and 4 (gastric cancer, 5% ), thrombosis (breast cancer, 2.1% to 3.7% ), interstitial pneumonia"
        ],
        "description": "protocol-of-trastuzumab \u2192 \u5291\u91cf\u4ee5\u53ca\u526f\u4f5c\u7528"
    },
    "ESMO Checklist_Early and Locally Advanced Non-Small Cell Lung Cancer": {
        "prefix": "EarlyNSCLC",
        "body": [
            "## MEDICAL HISTORY AND RISK FACTORS",
            "",
            "Past personal medical history and vascular risk factors:",
            "Past surgical history:",
            "Concurrent medication:",
            "Allergies:",
            "Smoking history: __pack/y from age__ to age__",
            "Alcohol consumption:",
            "",
            "---",
            "",
            "## PHYSICAL EXAM",
            "",
            "(PRESENT MEDICAL CONDITIONS)",
            "",
            "Normal weight: Height: BMI",
            "Main symptoms:",
            "Weight loss:",
            "ECOG Performance Status:",
            "ENT Examination:",
            "alert<> and oriented<>, appeared in no distress<>",
            "No< Anemia > conjunctival pallor,<> no<> scleral icterus",
            "HEENT: no<> oral thrush,<> no neck LAP",
            "Chest: bilateral<> clear<> breath sounds",
            "Heart: regular rhythm,<> normal rate,<>no murmur",
            "Abd: non<>distended, normo<>active BoS, nontender",
            "Ext: warm, <bilateral 2+>no<> pitting edema",
            "",
            "### Assessment",
            "",
            "# Lung adenocarcinoma",
            "",
            "## DIAGNOSIS AND CLINICAL STAGING",
            "",
            "- < date > PET/CT scan:",
            "- < date > Bronchoscopy:",
            "- < date > EBUS/EUS:",
            "- < date > TNM stage and grade:",
            "",
            "### HISTOLOGICAL ANALYSIS",
            "",
            "- Core biopsy of primary tumour:",
            "- Non-squamous:",
            "  - Tested for EGFR mut. PD-L1, method used",
            "- Squamous:",
            "  - Tested for PD-L1, method used",
            "- Tissue material available/stored for future molecular analyses YES NO",
            "- CBC/DC, Liver Enzymes, LDH, Calcium, Albumin, Renal, Function",
            "- IF the patient is scheduled for radical treatment, the following tests have been considered",
            "  - (Stage III) Brain MRI, preferably to contrast-enhanced CT-scan",
            "  - Lung function tests",
            "  - Cardio-vascular check-up",
            "- Timeline for further work-up has been checked and it is tight enough",
            "",
            "### MDT discussion and decision",
            "",
            "- Treatment options have been discussed with the patient and strategy accepte",
            "  - Surgery Performed Planned",
            "  - SBRT Radiotherapy Radiofrequency ablation (or similar ablative approach)",
            "  - Neoadjuvant chemotherapy",
            "  - Adjuvant radiotherapy Adjuvant chemotherapy",
            "  - Chemoradiation Concurrent Sequential",
            "  - Durvalumab maintenance",
            "  - Supportive and palliative care",
            "  - Enrolment in a clinical trial"
        ],
        "description": "ESMO Checklist_Early and Locally Advanced Non-Small Cell Lung Cancer"
    },
    "neuroexam": {
        "prefix": "nelist",
        "body": [
            "## NEUROLOGY EXAM",
            "",
            "- A+Ox3 / E4V5M6 / JOMAC intact",
            "- CNII-XII grossly intact",
            "- UPPER ext.",
            "  - strength 5/5 throughout / normal tone",
            "  - intact to sharp and dull throughout",
            "  - DTR: Biceps 2+ / Triceps 2+ / Brachioradialis 2+",
            "  - Rapid Hand Movements intact, No Drift",
            "- LOWER ext.",
            "  - strength 5/5 throughout / normal tone",
            "  - intact to sharp and dull throughout",
            "  - DTR: Knee 2+ / Achilles 2+ / Babinski -/-",
            "  - SLRT: 90 degree",
            "  - Rapid Foot Tapping intact",
            "- COORDINATION",
            "  - F-N-F: no dysmetria or dyssynergia",
            "  - H-N-S: intact ; DDK -/-",
            "  - Romberg test intact; Steady Gait"
        ],
        "description": "neuroexam"
    },
    "assessment of hospitalized cancer patients": {
        "prefix": "temp.consult",
        "body": [
            "== assessment ==",
            "",
            "== plan =="
        ],
        "description": "assessment of hospitalized cancer patients"
    },
    "HBV_pathway": {
        "prefix": "hbv.pathway",
        "body": [
            "- moderate risk: HBsAg-positive individuals receieved cytotoxic chemotherapy",
            "- confirm HBV/HCV profiles prior to administering preventive anti-viral agents for HBV flare-up prophylaxis during chemotherapy.",
            "- start entecavir concurrently or prior to initiating chemotherapy",
            "  - maintained for at least 6 months after withdrawal of immunosuppression",
            "  - duration of chemotherapy: `___`/`___`/`___` to `___`/`___`/`___` (estimated)",
            "  - explain adverse effects:",
            "    - headache, fatigue, dizziness, nausea reported in 22% of patients.",
            "- monitor if HBV reactivation:",
            "  - previously had undetectable HBV DNA -> detectable HBV DNA",
            "  - 10x to 100x fold increase in HBV DNA",
            "  - HBsAg negative/anti-HBc positive becomes HBsAg positive"
        ],
        "description": "HBV_pathway"
    },
    "KPS": {
        "prefix": "kps",
        "body": [
            "- 100% Healthy, no symptoms or signs of disease",
            "- 90% Capable of normal activity, few symptoms or signs of disease",
            "- 80% Normal activity with some difficulty, some symptoms or signs",
            "- Still go for work? `___`",
            "- 70% Caring for self, not capable of normal activity or work",
            "- 60% Requiring some help, can take care of most personal requirements",
            "- 50% Requires help often, requires frequent medical care",
            "- Someone have to care about this patient 24hr `___`",
            "- 40% Disabled, requires special care and help",
            "- 30% Severely disabled, hospital admission indicated but no risk of death",
            "- 20% Very ill, urgently requiring admission, requires supportive measures or treatment"
        ],
        "description": "KPS"
    },
    "Iron-supplementation": {
        "prefix": "fe",
        "body": [
            "? IV (not PO) if NYHA II/III, EF \u226440%, Fe-defic (ferritin <100 or 100\u2013 300 & TSAT <20%). ~20% \u2193 HF hosp. (Lancet 2020;396:1895)."
        ],
        "description": "Iron-supplementation"
    },
    "Procedure_Note_LP": {
        "prefix": "LP",
        "body": [
            "- indication: suspected meningitis`___`intrathecal chemotherapy`___`rule out leptomeningeal seeding`___`",
            "- left`___`right`___` lateral position",
            "- L`___`/`___` lumbar interspace.",
            "- opening pressure: `___` cmH2O",
            "- CSF was collected into 1 `___` tubes",
            "- intrathecal chemotherapy: methotrexate `___` mg",
            "- estimated blood: 0 ml",
            "",
            "The patient tolerate the procedure well without complication, and will lying supine for 4 hours."
        ],
        "description": "Procedure_Note_LP"
    },
    "Procedure_Note_BMBx": {
        "prefix": "BMBX",
        "body": [
            "- indication: `___`",
            "- diagnosis: `___`",
            "- site: Rt `___` Lt `___` bilateral `___` superior posterior iliac crest",
            "- position: prone `___`"
        ],
        "description": "Procedure_Note_BMBx"
    },
    "Procedure_Note_Intubation": {
        "prefix": "RSI",
        "body": [
            "time: `___`:`___`",
            "",
            "- indication: respiratory distress `___`",
            "- pre-oxygenation: HFNC 15L for 3 minutes",
            "- plan B: laryngeal mask airway",
            "- induction medication:",
            "  - Propofol 10ml (50-70 kg) `___`",
            "  - Midazolam 2mL (50kg) `___`",
            "  - Succinylcholine 0.5ml (50 kg \u4ee5\u4e0b) `___`",
            "- GlideScope video laryngoscopes, with hyperangulated blade",
            "- endotracheal tube size: 7.5 Fr `___`",
            "- portable CXR: ETT tips 5 \u00b1 2 cm `___` above the carina",
            "- post-procedural vitals: `___`",
            "",
            "The patient tolerated the procedure well and there were no complications"
        ],
        "description": "Procedure_Note_Intubation"
    },
    "Procedure_Note_Pleural": {
        "prefix": "PLE",
        "body": [
            "- constraindication include coagulopathy (INR >2.0) or platelets <50: NIL `___`",
            "- Patient position: sitting.",
            "- Right `___` Left `___` sided",
            "- 10 `___` th intercostal space.",
            "- Amount: `___` mL",
            "- Estimated Blood Loss: minimal",
            "",
            "The patient tolerated the procedure well without complications."
        ],
        "description": "Procedure_Note_Pleural"
    },
    "Procedure_Note_Ascitic": {
        "prefix": "ASC",
        "body": [
            "- indication: symptom relief `___` diagnostic `___`",
            "- constraindication include Coagulopathy (INR >2.0) Platelets <50: NIL `___`",
            "- site: LLQ `___` RLQ `___`, with Z-track technique",
            "- samples were sent to the lab for analysis: `___`",
            "- amount: `___` ml,",
            "- color: translucent `___` yellow `___` brown `___` cloudy `___` turbid `___` blood tinged `___` grossly bloody `___` milky `___`",
            "- estimated blood loss: minimal",
            "",
            "The patient tolerated the procedure well without complications."
        ],
        "description": "Procedure_Note_Ascitic"
    },
    "Hyperglycemic crises checklist": {
        "prefix": "hypogly",
        "body": [
            "- ABCDE survey `___`",
            "- Establish IV access with two large-bore peripheral IV lines. `___`",
            "- Confirm diagnosis with:",
            "  - blood gas `___`",
            "  - BMP `___`",
            "  - serum osmolality `___`",
            "  - serum ketones `___`",
            "  - urine ketones `___`",
            "- Identify and treat life-threatening causes `___`",
            "  - e.g., MI, sepsis",
            "- Assess severity of DKA:",
            "  - Moderate:",
            "    - pH 7.0-7.24",
            "    - SodBicar: 10-15 mEq/L",
            "    - AG \\> 12 mEq/L",
            "    - MS: Alert or drowsy, or ( severe: Stuporous )",
            "- Begin fluid resuscitation with 0.9% NaCl.`___`",
            "- Replete potassium and maintain K+ levels at 4-5 mEq/L.`___`",
            "- Replete other electrolytes",
            "- Start continuous insulin IV infusion",
            "  - with hourly POC glucose checks once serum potassium is confirmed > 3.3 mEq/L.`___`",
            "- Consider bicarbonate if pH \\< 6.9 despite adequate fluid therapy.`___`",
            "- Adjust fluid resuscitation based on corrected sodium for hyperglycemia, serum glucose, and clinical response.",
            "  - Corrected serum sodium \u2265 135 mmol/L: 0.45% NaCl",
            "  - Corrected serum sodium < 135 mmol/L: 0.9% NaCl",
            "  - Add dextrose once POC glucose is below 250-300 mg/dL.",
            "- Identify and treat the underlying cause`___`",
            "  - e.g., medication nonadherence, infection",
            "- Order monitoring labs",
            "  - e.g., BMP, serum osmolality, and blood gas every 2-4 hours`___`",
            "- Consider endocrine consult.`___`",
            "- Consider ICU admission.`___`"
        ],
        "description": "Hyperglycemic crises checklist"
    },
    "template-is-non-a-good-ide": {
        "prefix": "slide_open_and_end",
        "body": [
            "<!-- _paginate: false -->",
            "<!-- _header: '' -->",
            "",
            "### Book: R for Data Science (2e)",
            "",
            "<br>",
            "",
            "## <!--fit--> Section I: Whole Game",
            "",
            "## \u6797\u5354\u9706"
        ],
        "description": "template-is-non-a-good-ide"
    },
    "prechemo_TNBC": {
        "prefix": "prechemo_TNBC",
        "body": [
            "< Diagnostic >",
            "",
            "- for recurrence early stage TNBC, consider CT scan for chest, abdomen, and pelvis",
            "- consider PET-CT",
            "",
            "< Theraputic >",
            "",
            "- arranged Por-A implentation",
            "- Cyle 1-4 (Cycled every 3 weeks)",
            "  - Doxorubicin 60 mg/m2, Cyclophosphamide 600 mg/m2",
            "  - Pembrolizumab 200 mg (out-of-pocket expense $65,226NTD x 2 vial x 4 = 521,808)",
            "- Cycle 5-8 (Cycled every 3 weeks)",
            "  - Docetaxel\\* 60 mg/m2",
            "  - Pembrolizumab 200 mg (out-of-pocket expense $65,226NTD x 2 vial x 4 = 521,808)",
            "- then proceed to surgery",
            "- post-op XRT if indicated",
            "",
            "< Education >",
            "",
            "- explained reason of < adjuvant / neoadjuvant > chemotherapy: achieve pathological complete response (pCR), to cure and lower the risk of recurrence/metastasis.",
            "- explained chemotherapy schedule",
            "- explained potential chemotherapy toxicities:",
            "  - <> cyclophosphamide: bone marrow function compromised, hemorrhagic cystitis",
            "  - <> doxorubicin: cardiotoxicity, with life-time culmucation 450-500 mg/BSA (300mg/BSA this course)",
            "  - <> docetaxel: stomatitis, persistent febrile neutropenia, cutaneous reactions, moderate neurosensory effects",
            "- explained potential ICI toxicities:",
            "  - pembrolizumab: skin rash pneumonitis, colitis, hepatitis, hypophysitis, thyroid dysfunction, diabetes mellitus",
            "- suggested high protein diet, not suggested chicken essence because it may confound the lab."
        ],
        "description": "prechemo_TNBC"
    },
    "ebc adjuvant": {
        "prefix": "A_EBC_ADJ",
        "body": [
            "- `___` Menopause, Premenopause",
            "- Adjuvant chemotherapy:",
            "  - `___` CAF X 6,",
            "  - `___` AC X 4 --> T X 4",
            "- Consult RT",
            "- `___` Letrozole x 5 years, Tamoxifen x 5~10 years or consider LHRH agonist + AI for 5 years",
            "- 2023/`___`/`___`: explain purpose of adjuvant treatment is to reduce further risk of local recurrence and distant mets, but not 100%",
            "  - Offer oncotype DX for evaluation but self-paid",
            "  - Arrange #1 CAF/AC on `___`/`___` (4~5th week), RTC on `___`/`___` and check lab for prechemotherapy evaluation",
            "  - Olanzepine HS self-paid, akyenzo, dexam, and primperan for emeis.",
            "  - Do cardiac echo if has risk factor: hx of CAD",
            "  - schedule vascular assessment, rehabilitation, nutritional assessment, dental check before chemotherapy"
        ],
        "description": "ebc adjuvant"
    }
}